^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    nafamostat

    i
    Other names: FUT-175, CKD-314
    Company:
    Generic mfg.
    Drug class:
    TMPRSS2 inhibitor, Serine protease inhibitor
    Related drugs:
    16d
    Multifaceted anticancer activity of nafamostat mesylate in human fibrosarcoma: first evidence of mitochondrial apoptosis and suppressed MMP-2/-9 mRNA expression. (PubMed, BMC Pharmacol Toxicol)
    This study provides the first evidence that nafamostat mesylate exerts multifaceted anticancer effects in HT1080 fibrosarcoma cells, targeting proliferation, migration, apoptosis, and invasion. These findings support the potential repurposing of nafamostat mesylate as a therapeutic agent for fibrosarcoma and warrant further preclinical investigations to evaluate its translational applicability.
    Journal
    |
    MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9) • ANXA5 (Annexin A5)
    |
    nafamostat
    1m
    Comparison of the efficacy and safety of nafamostat mesylate and heparin in blood purification therapy for patients with severe acute pancreatitis: A randomized controlled trial (ChiCTR2500111161)
    P4, N=140, Not yet recruiting, Weifang People's Hospital; Weifang People's Hospital
    New P4 trial
    |
    nafamostat
    1m
    The Safety and Efficacy of Different Anticoagulation Strategies in Double Filtration Plasmapheresis Therapy (ChiCTR2500109547)
    P=N/A, N=300, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New trial
    |
    nafamostat
    1m
    Clinical research on nafamostat mesylate for injection (ChiCTR2500107352)
    P3, N=220, Not yet recruiting, The Second Affiliated Hospital of Nanjing Medical University; The Second Affiliated Hospital of Nanjing Medical University
    New P3 trial
    |
    nafamostat
    2ms
    NEPHRO: Nafamostat Efficacy in Phase 3 Registrational CRRT Study (clinicaltrials.gov)
    P=N/A, N=70, Recruiting, Talphera, Inc | N=166 --> 70
    Enrollment change
    |
    nafamostat
    2ms
    NEPHRO: Nafamostat Efficacy in Phase 3 Registrational CRRT Study (clinicaltrials.gov)
    P=N/A, N=166, Recruiting, Talphera, Inc | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    nafamostat
    4ms
    Feasibility study of blood sample collection from hemodialysis extracorporeal circulation circuit instead of blood vessel for monitoring the anticoagulant effect of nafamostat mesylate in continuous blood purification therapy (ChiCTR2500107232)
    P=N/A, N=0, Not yet recruiting, Aerospace Center Hospital; Aerospace Center Hospital
    New trial
    |
    nafamostat
    4ms
    DEFINE - Evaluating Therapies for COVID-19 (clinicaltrials.gov)
    P1/2, N=71, Completed, University of Edinburgh | Recruiting --> Completed | N=200 --> 71
    Trial completion • Enrollment change
    |
    nafamostat
    4ms
    Comparative Study of Citrate versus Nafamostat for CRRT in Patients with Sepsis-Associated Acute Kidney Injury (ChiCTR2500106976)
    P=N/A, N=112, Not yet recruiting, Zhongnan Hospital of Wuhan University; Zhongnan Hospital of Wuhan University
    New trial
    |
    nafamostat
    4ms
    Regional Citrate Anticoagulation versus No Anticoagulation for CRRT in Patients with Increased Bleeding Risk (ChiCTR2500104138)
    P=N/A, N=190, Recruiting, The First Affiliated Hospital, the Air Force Medical University; The First Affiliated Hospital of the Air Force Medical University
    New trial
    |
    nafamostat
    5ms
    TMPRSS2: A Key Host Factor in SARS-CoV-2 Infection and Potential Therapeutic Target. (PubMed, Medeni Med J)
    Several TMPRSS2 inhibitors, including serine protease inhibitors, such as camostat mesylate and nafamostat, have demonstarted promise in blocking viral entry. The presence of TMPRSS2-ERG gene fusion, commonly found in prostate cancer, has also been linked to altered COVID-19 susceptibility, suggesting a complex interplay between viral infection and cancer biology. This review also discusses future perspectives, including large-scale genomic studies to identify high-risk individuals, the development of next-generation TMPRSS2 inhibitors, and potential broad-spectrum antiviral therapies targeting TMPRSS2.
    Journal
    |
    ERG (ETS Transcription Factor ERG) • TMPRSS2 (Transmembrane serine protease 2)
    |
    TMPRSS2-ERG fusion
    |
    nafamostat
    6ms
    Comparison of Anticoagulant Effects between Nafamostat Mesylate and Citrate in Continuous Renal Replacement Therapy: A Retrospective Cohort Study (ChiCTR2500101672)
    P=N/A, N=273, Not yet recruiting, Peking University Shenzhen Hospital; Peking University Shenzhen Hospital
    New trial
    |
    nafamostat